EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model

Jeremy Fraysse iD, Sarah-Jane Anderson, Justin C Smith, Derrick D Matthews, Supriya Sarkar, Filipa de Aragao, Rob Blissett

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0312369 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Jeremy Fraysse und 6 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, Health Outcomes, The Netherlands. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Homosexuality, Male, Models, Theoretical. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The US faces substantial demographic and geographic disparities in both HIV burden and access to pre-exposure prophylaxis (PrEP), an effective strategy to prevent HIV acquisition. Long-acting cabotegravir (CAB) is a novel, injectable PrEP option which demonstrated superior reduction in risk of HIV acquisition compared to daily-oral PrEP in the HPTN083 trial. We modelled the impact of increased PrEP initiations and the introduction of long-acting CAB on HIV incidence among men who have sex with men (MSM) in Atlanta, Georgia, a population with a high burden of HIV. The Georgia Department of Public Health has set an ambitious 25% HIV incidence reduction target, which could be reached with a daily-oral PrEP coverage of 42.2%. However, the target could be achieved at lower levels of PrEP coverage (34.6%) if a mix of PrEP modalities was used, such as an equal split of long-acting CAB PrEP and daily-oral PrEP. Our results clearly demonstrate that broadening access to new PrEP options has the potential to facilitate the achievement of public health HIV incidence reduction goals at plausible levels of PrEP coverage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisHomosexuality, MaleModels, TheoreticalAnti-HIV AgentsHumansMaleGeorgiaIncidencePyridonesAdultDiketopiperazines

Substanzen

Anti-HIV AgentsPyridonescabotegravirDiketopiperazines

Autor:innen und Institutionen

  • ViiV Healthcare, Health Outcomes, The Netherlands.
  • GlaxoSmithKline, Value, Evidence & Outcomes, United Kingdom.
  • Campaign to End AIDS at Positive Impact Health Centers, Georgia, United States of America.
  • Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.
  • Weitzman Institute, Moses/Weitzman Health System, United States of America.
  • ViiV Healthcare, Epidemiology & Real-World Evidence, Durham, NC, United States of America.

ORCID-Profile: Jeremy Fraysse

Förderung

  • ViiV Healthcare

Zitieren

APA

Fraysse, J., Anderson, S. J., Smith, J. C., Matthews, D. D., Sarkar, S., de Aragao, F., & Blissett, R. (2025). Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model. PLOS ONE. https://doi.org/10.1371/journal.pone.0312369

Vancouver

Fraysse J, Anderson SJ, Smith JC, Matthews DD, Sarkar S, de Aragao F, et al. Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model. PLOS ONE. 2025. doi:10.1371/journal.pone.0312369

BibTeX
@article{Fraysse2025,
  author = {Fraysse, Jeremy and Anderson, Sarah-Jane and Smith, Justin C and Matthews, Derrick D and Sarkar, Supriya and de Aragao, Filipa and Blissett, Rob},
  title = {Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0312369}
}
Kostenlos starten →